[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@zipjet Avatar @zipjet zipjet

zipjet posts on X about $ocul, $shak, imo, $tgtx the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence stocks XXXX% finance XXXX% cryptocurrencies XXXX% technology brands XXXX%

Social topic influence $ocul #14, $shak 3.13%, imo 3.13%, $tgtx 3.13%, accounting 3.13%, future 3.13%, $lqda 3.13%, $uthr 3.13%, insurance XXXX%

Top accounts mentioned or mentioned by @lucy3370 @martychargin @perryglasenberg @paperboy2009 @biowreck2022 @lars57360069 @jonahlupton @commonsenseplay @safwan22025 @mbamcnulty @goldriversports @diyinvestguy @jeremyfalmouth @john_hersc79276 @sububoston @behrooznajafi @vxeel @ngyojiw @svix_enjoyoor @paperhands91

Top assets mentioned Ocular Therapeutix, Inc. (OCUL) Shakita Inu (SHAK) TG Therapeutics, Inc. (TGTX) Liquidia Corporation Common Stock (LQDA) United Therapeutics, Corp. (UTHR)

Top Social Posts

Top posts by engagements in the last XX hours

"@JonahLupton @commonsenseplay $SHAK is worthless IMO. Ate there once. Never again"
X Link 2025-12-08T01:01Z 2922 followers, XXX engagements

"$OCUL 📰 Summary: Ocular Therapeutix Accelerates Plans for Wet AMD Drug AXPAXLI Ocular Therapeutix Inc. has announced it now intends to submit a New Drug Application (NDA) for AXPAXLI (OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD) following positive year-one data from its ongoing SOL-1 Phase X clinical trial. Key Points: Accelerated Submission: The decision to potentially submit the NDA after only the first year of data is based on recent public statements from FDA leadership regarding the potential for a single registrational trial for new product candidates as"
X Link 2025-12-08T12:33Z 2922 followers, XXX engagements

"@safwan22025 $TGTX Those earnings are really an accounting artifact. There were no sales to support the vast majority of those EPS no cash flows. Those earnings are essentially a recognition that the prior losses will shelter future earnings"
X Link 2025-12-08T14:26Z 2922 followers, XXX engagements

"@diyinvestguy Not a hedge. But a reasonable pair trade is long $LQDA and short $UTHR. I think finding the XXX patent invalid would see UTHR drop 50-100 points"
X Link 2025-12-08T01:17Z 2921 followers, 1202 engagements

"$OCUL We all get some right and some wrong. Some friends told me they wanted to sell OCUL. I told them I thought it would be over XX by the end of this year. They sold at $8.35"
X Link 2025-12-08T14:37Z 2922 followers, 1445 engagements

"Without competition you can hide prices. We have created a monster with laws like certificates of need. High time we return to free markets and unleash competition. Of course entrenched interests with enormous power and financial resources will resist. Namely: Hospitals Insurance companies and governments"
X Link 2025-12-10T10:38Z 2922 followers, XXX engagements